Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Binimetinib, Encorafenib in patients with Melanoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.